FDA Approves First Daily Pill to Lower Bad Cholesterol

Millions of Americans with high cholesterol just got some welcome news: no more needles required.

The FDA approved Lipfendra on Thursday, the first daily pill that can lower dangerous LDL cholesterol as effectively as injections. Manufactured by Merck, the new medication offers the same powerful cholesterol reduction without the twice-monthly or monthly shots that many patients have been avoiding.

The timing couldn't be better. One in four American adults struggles with high LDL cholesterol, which silently builds fatty deposits in artery walls and raises the risk of heart attacks and strokes.

Until now, the most advanced cholesterol fighters called PCSK9 inhibitors were only available as expensive injections. Lipfendra changes that by blocking the same protein but in pill form, stopping the body from keeping LDL cholesterol in the blood.

The new pill carries a list price of about $300 monthly, compared to roughly $500 for comparable injections. Patients will need to check with their insurance to see their actual costs, and the medication should reach pharmacies within weeks.

The FDA based its approval on two major trials showing Lipfendra cut LDL levels by 56% to 59% compared to placebo pills. Those impressive results held steady across different patient groups, including people with familial hypercholesterolemia, a genetic condition causing severely high cholesterol.

The Ripple Effect

This approval opens doors for patients who couldn't access treatment before. Many people avoid injections due to needle anxiety, physical limitations, or simple preference for pills over shots.

Dr. Jeffrey Berger, director of the Center for the Prevention of Cardiovascular Disease at NYU Langone Heart, explained the significance: "Lowering LDL is one of the most effective tools we have in preventive cardiology because it directly targets a major driver of heart disease."

The pill works alongside healthy eating and exercise, and it's especially valuable for patients already taking statins who still haven't reached safe cholesterol levels. Dr. William Soliman, founder of the Accreditation Council for Medical Affairs, noted that the oral format could broaden adoption since both patients and doctors are more comfortable with pills than injections.

Heart disease remains America's leading killer, making any tool that helps more people control their cholesterol a potential lifesaver for thousands of families.